Jevtana: new option for metastatic prostate cancer

Jevtana (cabazitaxel) is a novel taxane and is licensed for the treatment of hormone refractory metastatic prostate cancer in patients who have been previously treated with docetaxel.

Jevtana increases median overall survival compared with mitoxantrone
Jevtana increases median overall survival compared with mitoxantrone

PHARMACOLOGY

Cabazitaxel is a novel taxane antineoplastic agent, which stabilises the microtubule network by binding to tubulin, thereby preventing the breakdown required for cancer cell division.1

CLINICAL STUDIES

The open-label, randomised phase 3 TROPIC study (n=755) compared the efficacy and safety of cabazitaxel against mitoxantrone, both in combination with either prednisone or prednisolone, in patients with hormone-refractory metastatic prostate cancer who had previously received a docetaxel-containing regimen. The primary endpoint used was overall survival.2

The data were analysed on an intention to treat basis. At the cut-off for final analysis, median overall survival was longer in the cabazitaxel group (15.1 months) than in the mitoxantrone group (12.7 months; p<0.0001), indicating that cabazitaxel provides a 30% reduction in the risk of death compared with mitoxantrone.2

In addition, median progression-free survival was approximately doubled in patients treated with cabazitaxel (2.8 months) compared with those who received mitoxantrone (1.4 months; p<0.0001).2

There was no significant difference between treatment arms with regard to pain progression or pain response.2

REFERENCES

  1. Jevtana Summary of Product Characteristics, March 2011.
  2. de Bono JS et al. Lancet 2010; 376: 1147–54.

View Jevtana drug record

Further Information: Sanofi–aventis


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases